Skip to Content


Generic Name: Carboplatin
Class: Antineoplastic Agents
VA Class: AN900
CAS Number: 41575-94-4


  • Use only under the supervision of a qualified clinician experienced in the use of cytotoxic therapy.1 Use only when adequate treatment facilities for appropriate management of therapy and complications are available.1

  • Dose-related bone marrow suppression may result in infection and/or bleeding.1 Anemia may be cumulative and may require transfusion support.1

  • Vomiting is a common adverse effect.1 201

  • Anaphylactic-like reactions may occur within minutes of administration.1 Administer epinephrine, corticosteroids, and/or antihistamines to relieve symptoms.1


Antineoplastic agent; platinum-containing compound.1 2 3 4 5 6 92 93

Uses for Paraplatin

Carboplatin and cisplatin appear to have similar efficacy in the treatment of platinum-responsive ovarian tumors,1 5 9 10 11 12 60 137 184 185 lung cancers,18 29 121 137 and certain head and neck cancers;17 137 carboplatin is less effective than cisplatin in certain testicular cancers.24 78 137 193

Because carboplatin and cisplatin have different toxicity profiles,1 2 3 4 5 8 9 10 11 12 68 carboplatin may be effective in patients with platinum-responsive tumors who are unable to tolerate cisplatin because of renal impairment, refractory nausea, hearing impairment, or neuropathy;4 40 137 cisplatin may be preferred in patients with decreased bone marrow reserve or high risk of sepsis or those requiring anticoagulation therapy.10 137

Ovarian Cancer

Treatment of ovarian cancer (alone and as combination therapy).1 9 29

Combination therapy with platinum-containing agent (carboplatin or cisplatin) and paclitaxel is the preferred regimen for initial treatment of advanced epithelial ovarian cancer; therapy with platinum-containing agent and paclitaxel is superior to therapy with platinum-containing agent and cyclophosphamide.9 29 60 137 139 147 Carboplatin is as effective as but less toxic than cisplatin when used in combination with paclitaxel184 185 or cyclophosphamide.10 11

Carboplatin in combination with docetaxel has been used for the first-line treatment of ovarian cancer and has demonstrated similar efficacy and a different tolerability profile (i.e., more hematologic toxicity but less neurotoxicity) compared with carboplatin in combination with paclitaxel.196

Has been used as a single agent in the first-line treatment of advanced ovarian cancer.9 29 Role remains to be established, but some clinicians consider single-agent carboplatin a reasonable option.29 137 187

Used alone as second-line therapy for palliative treatment of recurrent ovarian cancer in patients with platinum-sensitive disease;1 2 9 nonplatinum-based regimens generally preferred for retreatment of patients with platinum-refractory disease.2 9 60 72

Being studied for use in combination regimens for second-line treatment of advanced ovarian epithelial cancer.9 188 189

Has been used alone or in combination therapy for adjuvant treatment of early-stage ovarian cancer.9 179 180 Survival benefit may be limited to patients whose disease is associated with poorer prognosis.137 179

Lung Cancer

Treatment of small cell lung cancer as a component of combination regimens.3 4 18 19 20 29 75 76

An active agent in non-small cell lung cancer.29 121 132 133 137 152 177 178 197 198

Cervical Cancer

Role in the treatment of cervical cancer remains to be established.157 166 Current evidence supports use of cisplatin in chemotherapy regimens given concurrently with radiation therapy in patients with locally advanced cervical cancer; similar benefit from carboplatin-containing chemotherapy cannot be assumed.157 166

An active agent in the treatment of metastatic or recurrent cervical cancer.29 163 164 165 May be considered an alternative to cisplatin, particularly in patients with nephrotoxicity or neurotoxicity caused by advanced cervical tumor who are not candidates for cisplatin therapy.163 164 165

Head and Neck Cancer

May be useful in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck.3 4 5 15 16 17 29 41 128 135 200

Wilms’ Tumor

Has shown activity in the management of Wilms’ tumor.29 65

Brain Tumors

Has been used for palliative treatment of various primary brain tumors.3 29

Has shown activity in the treatment of progressive or recurrent low-grade gliomas in children;29 56 57 responses observed in adults with recurrent glioma, including those who had received previous chemotherapy with nitrosoureas.29 170 171

Has shown activity in the treatment of recurrent medulloblastoma.56 130

Combination therapy with platinum-containing agent (cisplatin or carboplatin) and etoposide is used for treatment of intracranial germ cell tumors.29 169 176


Used (as combination therapy) fortreatment of neuroblastoma.26 29

Testicular Cancer

Cisplatin-based regimen (i.e., cisplatin/etoposide or cisplatin/etoposide/bleomycin) is more effective than carboplatin-based regimen (i.e., carboplatin/etoposide or carboplatin/etoposide/bleomycin) for initial treatment of good-prognosis metastatic nonseminomatous germ cell tumor; generally reserve use of carboplatin regimen for patients who do not tolerate or who refuse cisplatin.24 78 137 193

Limited data suggest that high-dose carboplatin and etoposide may be effective in some patients with relapsed or refractory germ cell tumors.23 30 59

Bladder Cancer

Has been substituted as a less toxic alternative to cisplatin in the treatment of advanced bladder cancer in some patients receiving combination chemotherapy.143 146

Combination therapy with paclitaxel followed by carboplatin is being studied in patients with advanced bladder cancer, including those with abnormal renal function.97 131 168 190


Has been used in combination with etoposide in a limited number of children with recurrent or progressive retinoblastoma.102 106

Breast Cancer

Has been used in a limited number of patients with metastatic breast cancer.199

Endometrial Cancer

Being studied in the treatment of advanced or recurrent endometrial cancer.195

Paraplatin Dosage and Administration


  • Consult specialized references for procedures for proper handling and disposal of antineoplastics.1

  • Carboplatin is considered a moderate antiemetic risk antineoplastic (i.e., 30–90% incidence of emesis without antiemetics).201 Antiemetic therapy (e.g., a 5-HT3 receptor antagonist and dexamethasone) is recommended to prevent nausea and vomiting.201 (See Emetogenic Effects under Cautions.)

  • Pretreatment and posttreatment hydration and/or diuresis are not necessary.1 10 11 24 27 37 (See Renal Effects under Cautions.)


IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV infusion;1 also has been administered intraperitoneally.2 3 4 32 43 47

Needles, syringes, catheters, and IV administration sets that contain aluminum parts which may come in contact with carboplatin should not be used for preparation or administration.1


Reconstitute vial containing 50, 150, or 450 mg of carboplatin powder for injection with 5, 15, or 45 mL, respectively, of sterile water for injection, 5% dextrose injection, or 0.9% sodium chloride injection to provide a solution containing 10 mg/mL.b

Resulting solutions can be further diluted to concentrations as low as 0.5 mg/mL with 5% dextrose injection or 0.9% sodium chloride injection.b

Reconstituted solutions contain no preservatives; solutions preferably should be prepared immediately before use.b


May be diluted with 0.9% sodium chloride injection or 5% dextrose injection to a concentration as low as 0.5 mg/mL.1

Rate of Administration

Administer by IV infusion over a period of ≥15 minutes;1 2 4 10 13 25 27 42 also has been administered by continuous IV infusion over 24 hours.1 2 3


Base dosage on the clinical, renal, and hematologic response and tolerance of the patient in order to obtain optimum therapeutic response with minimum adverse effects.1 10 11

Initial dosage can be based on body surface area, but dosage may be more accurately calculated using formula dosing methods based on the patient’s renal function.1 81 82 83 84 85 93 107 108 137 (See Methods for Individualization of Dosage under Dosage and Administration.)

When used as a component of a multiple-drug regimen, consult published protocols for the dosage of each chemotherapeutic agent and the method and sequence of administration.


Ovarian Cancer
Initial Therapy for Advanced (Stage III and IV) Ovarian Carcinoma

Initially, 300 mg/m2 given in combination with cyclophosphamide.1 10 11 Adjust subsequent dosage according to the patient’s hematologic tolerance of the previous dose (see Dosage Adjustment in the Treatment of Ovarian Cancer); do not administer doses until hematologic function is within acceptable limits.1

Alternatively, calculate dosage using formula dosing methods (see Methods for Individualization of Dosage).1 81 82 83 84 85 93 107 108 137

A course of carboplatin consists of single doses administered once every 4 weeks (or longer if delayed for hematologic toxicity) for a total of 6 cycles.1 10 11 69 70 71

Secondary Treatment of Advanced Ovarian Cancer

Initially, 360 mg/m2 as monotherapy.1 Administer drug once every 4 weeks (or longer if delayed for hematologic toxicity).1 Adjust subsequent dosage according to the patient’s hematologic tolerance of the previous dose (see Dosage Adjustment in the Treatment of Ovarian Cancer); do not administer doses until hematologic function is within acceptable limits.1 137

Dosage Adjustment in the Treatment of Ovarian Cancer
Dosage Adjustment Based on Hematologic Response to Previous Dose

Hematologic Toxicity

Recommended Dosage Adjustment

No hematologic toxicity (platelet count >100,000/mm3 and neutrophil count >2000/mm3)

Increase dosage by 25%1 10 11

Mild or moderate hematologic toxicity (platelet count 50,000–100,000/mm3 or neutrophil count 500–2000/mm3)

No adjustment in dosage1 10 11

Moderate to severe hematologic toxicity (platelet count <50,000/mm3 or neutrophil count <500/mm3)

Decrease dosage by 25%1 10 11 137

Other Malignant Neoplasms

Consult published protocols for dosages and methods and sequences of administration. In general, escalation of dosages above 400 mg/m2 results in substantial hematologic toxicity, but high-dose carboplatin (900–2000 mg/m2) has been used with colony-stimulating factors,40 67 121 autologous bone marrow rescue, and/or peripheral stem cell rescue.28 30 37 40 59 111 137

Methods for Individualization of Dosage

Alternative methods for calculating initial carboplatin dosage have been suggested based on the patient’s pretreatment renal function or pretreatment renal function and desired platelet nadir.1 38 81 82 83 84 85 93 107 108

Calvert Formula

Calculation is based on the patient’s GFR (in mL/minute) and the target AUC (in mg/mL per minute).1 81 82 83 93 137 Dosage is calculated in mg, not mg/m2.1

Calvert Formula for Carboplatin Dosing:

total dose (mg) = target AUC (in mg/mL per min) × [GFR (in mL/min) + 25]

A target AUC of 5 (range: 4–6) mg/mL per minute appears to provide the most appropriate dosage range for use of carboplatin alone in patients previously treated with chemotherapeutic agents.1 82 83 93

Actual Toxicity in Previously Treated Patients1828393

AUC (mg/mL x min)

Percentage of Patients with Grade 3 or 4 Thrombocytopenia

Percentage of Patients with Grade 3 or 4 Leukopenia







For patients who previously did not receive chemotherapy, a target AUC of 7 (range: 6–8) mg/mL per minute has been recommended when carboplatin is used alone.82 83 93 Higher target AUCs (e.g., 7.5 mg/mL) also have been used (e.g., when carboplatin was used as a component of high-intensity dosing with paclitaxel and a hematopoietic agent for non-small cell lung carcinoma).121 Subsequent carboplatin dosage has been adjusted according to hematologic tolerance to the previous dose (e.g., reducing the dose by 25% for moderate to severe hematologic toxicity).121

Formula is not sufficiently accurate to determine dosage for children or for adults with severe renal impairment (i.e., GFR <20 mL/minute); therefore, do not use this formula in such patients.83 Consult specialized references for an alternative pediatric formula.83 93 119 120

Chatelut (French) Formula

Method does not require determination of GFR.84 85 93 Dosage is calculated in mg, not mg/m2.84 93

Chatelut (French) Formula for Carboplatin Dosing:

total dose (mg) = target AUC (in mg/mL per min) × carboplatin clearance (in mL/min)

When carboplatin clearance is calculated as follows:

Carboplatin Clearance:

Carboplatin clearance (mL/min) = (0.134 × wt) + ([218 × wt × (1 − {0.00457 × age})] × [1 − {0.314 × gender}] / serum creatinine (µmol/L)) (where weight is in kg, age is in years, and gender is 0 for males and 1 for females)

Do not use this formula for calculating dosage in pediatric patients or those undergoing hemodialysis.84

Special Populations

Renal Impairment

Reduce dosage in patients with Clcr <60 mL/minute.3 5 38

Dosage Recommendations for Patients with Impaired Renal Function

Baseline Clcr

Initial Dose

41–59 mL/min

250 mg/m2

16–40 mL/min

200 mg/m2

Incidence of severe leukopenia, neutropenia, or thrombocytopenia at these adjusted initial dosages is about 25%.1 Adjust subsequent dosage according to the patient’s hematologic tolerance to the previous dose.1 Experience in patients with Clcr <15 mL/minute is too limited to make dosage recommendations.1

Geriatric Patients

Use of dosing formulas incorporating estimates of GFR to determine dosage recommended in geriatric patients.1

Cautions for Paraplatin


  • History of sensitivity reactions to carboplatin or other platinum-containing compounds (e.g., cisplatin).1

  • Severe bone marrow depression or significant bleeding.1



Highly toxic drug with a low therapeutic index; therapeutic response is not likely to occur without some evidence of toxicity.1 10 11

Hematologic Effects

The major and dose-limiting adverse effects are dose-related hematologic toxicity (thrombocytopenia, leukopenia, neutropenia, and/or anemia).1 2 3 4 5 10 11 27 28 53 56 66 67 79 80 93 121

Myelosuppression appears to be most common and more severe in patients who received prior antineoplastic therapy (especially cisplatin-containing regimens), those concurrently receiving or having recently received other myelosuppressive drugs or radiation therapy, and those with renal impairment.1 3 38 53 66 67 82 83 84 85 93 101 121 137 Patients with poor performance status also appear to be at increased risk for severe leukopenia and thrombocytopenia.1 (See Interactions.)

At usual dosages, thrombocytopenia is more common and pronounced than leukopenia.53 82 93 Thrombocytopenia may be cumulative and occasionally require transfusions.121 Potential for infection.1 10 11

Anemia may be severe or symptomatic (e.g., accompanied by asthenia).1 10 11 Incidence appears to be cumulative.1 93 121 Transfusions may be required, particularly in patients receiving prolonged (>6 cycles) therapy.1 121 137

Monitor hematologic status carefully; perform peripheral blood counts at frequent intervals.1 121

Do not administer to patients with severe bone marrow depression or substantial bleeding.1 In patients who experience myelosuppression, withhold subsequent cycles until neutrophil counts are >2000/mm3 and platelet counts are >100,000/mm3.1

Treatment of severe hematologic toxicity may consist of supportive care, anti-infective agents for complicating infections, blood product transfusions, autologous bone marrow rescue, peripheral stem cell transplantation, and hematopoietic agents (colony-stimulating factors).1 30 40 93 121 137

Emetogenic Effects

Carboplatin is classified as an antineoplastic agent of moderate emetic risk (i.e., 30–90% incidence of emesis without antiemetics).201 Acute vomiting episodes are most common in patients who received prior emetogenic antineoplastic regimens (especially cisplatin-containing regimens) and in those receiving other emetogenic agents concurrently.1 201

Possible reduction in the incidence of nausea and vomiting when given as a 24-hour continuous IV infusion or IV in divided doses over 5 consecutive days rather than as a single IV infusion; however, efficacy of these schedules not established.1

Pretreatment with antiemetics may reduce incidence and severity of emesis; rarely, nausea and vomiting may be refractory to antiemetic therapy.1 3 93 103 136 201 For prevention of acute emesis, ASCO recommends a 2-drug antiemetic regimen consisting of a type 3 serotonin (5-HT3) receptor antagonist and dexamethasone given before carboplatin.201

For the prevention of delayed emesis following administration of carboplatin, ASCO recommends single-agent therapy with dexamethasone or a 5-HT3 receptor antagonist.201

Optimal use of antiemetics for prevention of acute and delayed emesis during early courses of therapy is the most important means for preventing anticipatory vomiting; behavioral modification, hypnosis, and drug therapy (e.g., benzodiazepine with or without conventional antiemetics) also may be useful.136 201

Peripheral Neuropathies

Possible peripheral neuropathies, generally sensory (e.g., paresthesia).1 10 11 93 Increased incidence in patients >65 years of age,1 those receiving prolonged therapy, and/or those who have received prior cisplatin therapy.1 93 121

Preexisting cisplatin-induced peripheral neurotoxicity generally does not worsen during carboplatin therapy.1

Otic Effects

Possible ototoxicity in patients receiving usual dosages of carboplatin in conjunction with cyclophosphamide.1

Concomitant use of ototoxic drugs (e.g., aminoglycosides, furosemide, ifosfamide) may increase risk.93 111 (See Interactions.)

Ocular Effects

Loss of vision (sometimes complete for light and colors) reported in patients receiving higher than usually recommended dosages; improvement and/or total recovery of vision has occurred within weeks following drug discontinuance.1 31

Hepatic Effects

Possible substantial abnormalities in liver function test results in patients receiving high doses (>4 times usual recommended dose) and autologous bone marrow transplantation.1

Fetal/Neonatal Morbidity and Mortality

May cause fetal harm; avoid pregnancy during therapy.1 If used during pregnancy or if patient becomes pregnant, apprise of potential fetal hazard.1

Embryotoxic and teratogenic in rats.1

Sensitivity Reactions

Hypersensitivity Reactions

Prior exposure to other platinum-containing agents increases the risk for carboplatin-induced allergic reactions, including anaphylaxis.1

Exposure (e.g., industrial) to platinum-containing compounds can cause asthma and immediate and delayed hypersensitivity reactions;33 36 93 consider the possibility that patients with a history of such exposure may be cross-sensitive to carboplatin.36

Observe closely for possible hypersensitivity reactions.1 61 Appropriate equipment for maintenance of an adequate airway and other supportive measures and agents for the treatment of such reactions (e.g., antihistamines, epinephrine, oxygen, corticosteroids) should be readily available when carboplatin is administered.1 61

General Precautions

Mutagenicity and Carcinogenicity

Mutagenic in vitro and in vivo.1

Carcinogenic potential not fully studied; however, drugs with similar mechanisms of action and evidence of mutagenic effects have been reported to be carcinogenic.1 Secondary malignancies reported in patients receiving carboplatin in combination with other agents.1

Renal Effects

Nephrotoxicity is less common and severe than that associated with cisplatin; concomitant IV hydration and diuresis generally not necessary.1 10 11 24 27 37 92 93 However, consider the possibility that nephrotoxicity may be potentiated by other nephrotoxic drugs.1 (See Interactions.)

Specific Populations


Category D.1 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)


Not known whether carboplatin or its platinum-containing products are distributed into milk.1 Discontinue nursing during therapy.1

Pediatric Use

Safety and efficacy not established.1

Limited experience in the treatment of germ cell tumors in adolescents ≥16 years of age,24 various brain tumors or neuroblastoma in children 6 months to 19 years of age,26 27 28 56 62 and Wilms’ tumor in children 2–15 years of age.66 79 80

Adverse effects reported to date in children are similar to those reported in adults and include hematologic toxicity (principally thrombocytopenia),27 28 56 66 79 80 adverse GI effects (e.g., nausea, vomiting),27 28 56 66 hypersensitivity reactions (e.g., urticaria, facial swelling, abdominal pain, coryza, cough),62 and hearing loss (particularly at higher than recommended doses in combination with other ototoxic agents).1

Geriatric Use

In clinical trials evaluating carboplatin as combination therapy for ovarian cancer, age was not found to be a factor for survival in patients ≥65 years of age relative to younger adults.1

Possible increased incidence of severe thrombocytopenia and carboplatin-induced peripheral neuropathy in adults ≥65 years of age compared with younger patients.1

Consider increased incidence of decreased renal function in geriatric population (see Geriatric Patients under Dosage and Administration).137

Renal Impairment

Increased risk of severe bone marrow depression in patients with renal impairment; monitor renal function carefully.1 40 82 83 84 85 93 Clcr appears to most accurately reflect kidney function in patients receiving carboplatin.1 40 82 83 84 85 93

Reduce dosage in patients with renal impairment.3 5 38 (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Thrombocytopenia,1 neutropenia,1 leukopenia,1 anemia,1 nausea,1 201 vomiting,1 201 electrolyte abnormalities (hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia),1 alkaline phosphatase elevations.1

Interactions for Paraplatin

Ototoxic Drugs

Hearing loss reported in children receiving carboplatin at higher than recommended doses in combination with other ototoxic drugs.1

Nephrotoxic Drugs

Possible potentiation of renal effects.1

Emetogenic Drugs

Concomitant use with emetogenic drugs or use in individuals who previously received emetogenic therapy is associated with an increased incidence of emesis.1 201

Specific Drugs and Therapies

Drug or Therapy




Increased risk of nephrotoxicity and/or ototoxicity1

Use with caution1

Antineoplastic agents

Prior antineoplastic therapy may increase risk of bone marrow suppression1

Myelosuppressive agents

Possible potentiation of hematologic toxicity1 3 66 67 101

Monitor carefully; manage dosage and time of administration to minimize additive toxic effects1 93 137

Radiation therapy

Possible potentiation of hematologic toxicity1 3 66 67 101

Monitor carefully; manage dosage and time of administration to minimize additive toxic effects1 93 137

Paraplatin Pharmacokinetics

Complex pharmacokinetics involve the parent compound as well as total platinum (protein-bound and nonprotein-bound platinum) and ultrafilterable platinum (carboplatin and nonprotein-bound carboplatin metabolites).1 2 3 4 43 44



Following IV infusion, peak plasma concentrations of carboplatin, total platinum, and ultrafilterable platinum occur immediately.3 42 44 46

Following intraperitoneal administration, peak plasma concentrations of total platinum, free platinum, and carboplatin are attained within 2–4 hours following instillation.3 4 43 47



Widely distributed into body tissues and fluids, with highest concentrations in the kidney, liver, skin, and tumor tissue;3 43 44 lower concentrations found in fat and brain.3 43 Also distributed into erythrocytes.43 44

Not known whether carboplatin or its platinum-containing products cross the placenta or are distributed into milk.1

Plasma Protein Binding

Carboplatin is not bound to plasma proteins, but degrades to platinum-containing products which rapidly bind to protein.45 49

<24% of platinum is bound to plasma proteins during the first 4 hours after IV administration of carboplatin; within 24 hours, 87% is protein bound.46



Metabolic fate has not been completely elucidated.1 3 4 5 6 7 43 No evidence to date that the drug undergoes enzymatic biotransformation; the bidentate dicarboxylate ligands of carboplatin are believed to be displaced by water, forming positively charged platinum complexes that react with nucleophilic sites on DNA.1 3 4 5 6 7 43

Elimination Route

Carboplatin and its platinum-containing product(s) are excreted principally in urine (predominantly via glomerular filtration).1 3 4 43 44

Carboplatin (as ultrafilterable carboplatin) is removed extensively by hemodialysis.54 86


Plasma elimination half-lives (t½β) for carboplatin and ultrafilterable platinum: 2–3 hours.1 43 44

Terminal elimination half-life (t½γ) for total platinum: 4–6 days.43 44

Special Populations

In patients with impaired renal function, renal clearance and total body clearance of platinum are reduced.3 4 38 54 In patients undergoing hemodialysis, t½β values for total and ultrafilterable platinum are increased compared with values in individuals with normal renal function.43 54




Injection Concentrate

25°C (may be exposed to 15–30°C).1 Protect from light.1

Discard unused solution 14 days after initial entry into vial.1

Discard diluted solutions 8 hours after preparation.1

Powder for Injection

20–25°C; protect from light.b

Reconstituted solutions are stable for 8 hours at room temperature (25°C).b Reconstituted solutions contain no preservatives; discard after 8 hours.b


For information on systemic interactions resulting from concomitant use, see Interactions.


Solution CompatibilityHID


Dextrose 5% in sodium chloride 0.2, 0.45, or 0.9%

Dextrose 5% in water

Sodium chloride 0.9%


Sodium bicarbonate 200 mM/L

Drug Compatibility
Admixture CompatibilityHID










Y-Site CompatibilityHID


Allopurinol sodium




Caspofungin acetate



Doxorubicin HCl liposome injection

Etoposide phosphate


Fludarabine phosphate

Gemcitabine HCl

Granisetron HCl


Melphalan HCl

Micafungin sodium

Ondansetron HCl



Palonosetron HCI

Pemetrexed disodium

Piperacillin sodium–tazobactam sodium





Topotecan HCl

Vinorelbine tartrate


Amphotericin B cholesteryl sulfate complex


  • Appears to exert effects by binding to DNA, thereby inhibiting DNA synthesis;2 3 4 5 6 7 92 93 effects are cycle-phase nonspecific.1 4 Antineoplastic activity may also involve other mechanisms.3 4 5 92 137

  • Must undergo activation before antineoplastic activity occurs.1 2 3 4 5 6 7 92 93 Both carboplatin and cisplatin are activated by an initial aquation reaction,3 4 5 92 but carboplatin is a more stable compound and is activated more slowly than cisplatin.1 3 4 5 6 7 92

    Higher concentrations of carboplatin than cisplatin are required to produce equivalent levels of DNA binding.1 3 4 5 6 7 At concentrations that produce equivalent levels of DNA binding, both drugs induce equal numbers of drug-DNA cross-links, resulting in equivalent lesions and biologic activity.1 3 4 5 6 7 Antitumor activity of carboplatin in mice is comparable to or slightly less than that of cisplatin.3

  • Further study needed to fully elucidate the extent of cross-resistance between cisplatin and carboplatin.2 Although some cisplatin-refractory tumors may respond to carboplatin, a high degree of cross-resistance appears to occur between the drugs.3 4 92

Advice to Patients

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed; necessity for clinicians to advise women to avoid pregnancy during therapy.1 Advise pregnant women of risk to the fetus.1

  • Importance of informing patients of other important precautionary information.1 (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name



Dosage Forms


Brand Names



For injection, concentrate, for IV infusion

10 mg/mL (50, 150, 450, or 600 mg)*

CARBOplatin for Injection


Bristol-Myers Squibb

For injection, for IV infusion

50 mg*

CARBOplatin for Injection


Bristol-Myers Squibb

150 mg*

CARBOplatin for Injection


Bristol-Myers Squibb

450 mg*

CARBOplatin for Injection


Bristol-Myers Squibb

AHFS DI Essentials. © Copyright 2018, Selected Revisions June 18, 2013. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.


1. Bristol-Myers Squibb. Paraplatin (carboplatin aqueous solution) injection prescribing information. Princeton, NJ; 2004 Jan.

2. Holland JF, Frei E, Bast RC et al, eds. Cancer medicine. 3rd ed. Philadelphia, PA. Lea & Febiger. 1993:743-54,1671.

3. Wagstaff AJ, Ward A, Benfield P et al. Carboplatin: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in the treatment of cancer. Drugs. 1989; 37:162-90. [PubMed 2649354]

4. Woloschuk DMM, Pruemer JM, Cluxton RJ Jr. Carboplatin: a new cisplatin analog. DICP. 1988; 22:843-9.

5. DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia, PA. JB Lippincott Company. 1993:390-400,810,1245.

6. Micetich KC, Barnes D, Erickson LC. Comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. Cancer Res. 1985; 45:4043-7.

7. Knox RJ, Friedlos F, Lydall DA et al. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum (II) and cis-diammine-(1,1-cyclobutanedicarbosylato) platinum (II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986; 46:1972-9. [PubMed 3512077]

8. McGuire WP. Primary treatment of epithelial ovarian malignancies. Cancer. 1993; 71:1541-50. [PubMed 8431892]

9. Ovarian epithelial cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2005 Jun 16.

10. Swenerton K, Jeffrey J, Stuart G et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1992; 10:718-26. [PubMed 1569444]

11. Alberts DS, Green S, Hannigan EV et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stage III and IV ovarian cancer. J Clin Oncol. 1992; 10:706-17. [PubMed 1569443]

12. Aabo K, Adnitt P, Adams M et al. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ. 1991; 303:884-93. [PubMed 1834291]

13. Trask C, Silverstone A, Ash CM et al. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. J Clin Oncol. 1991; 9:1131-7. [PubMed 2045855]

14. Lorusso V, Catino A, Leone B et al. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: pilot study. J Clin Oncol. 1993; 11:1952-6. [PubMed 8410121]

15. Amrein P. Current chemotherapy of head and neck cancer. J Oral Maxillofac Surg. 1991; 49:864-70. [PubMed 2072199]

16. Vokes EE, Weichselbaum RR, Lippman SM et al. Head and neck cancer. N Engl J Med. 1993; 328:184-94. [PubMed 8417385]

17. Al-Sarraf M, Metch B, Kish J et al. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University study. Cancer Treat Rep. 1987; 71:723-6. [PubMed 3300967]

18. Small cell lung cancer. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Mar 6.

19. Smith IE, Perren TJ, Ashley SA et al. Carboplatin, etoposide and ifosfamide as intensive chemotherapy for small-cell lung cancer. J Clin Oncol. 1990; 8:899-905. [PubMed 2159056]

20. Thatcher N, Lind M, Stout R et al. Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for ’limited’ stage small cell carcinoma of the bronchus. Br J Cancer. 1989; 60:98-101. [PubMed 2553090]

21. Hansen HH, Rorth M. Lung cancer. In: Pinedo HM, Longo DL, Chabner BA eds. Cancer chemotherapy and biological response modifiers annual 14. 1993:442-3.

22. Loehrerr PJ, Rynard S, Ansari R et al. Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. Cancer. 1992; 69:669-73. [PubMed 1309677]

23. Testicular cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2005 Feb 1.

24. Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol. 1993; 11:598-606. [PubMed 8386751]

25. Horwich A, Dearnaley DP, Nicholls J et al. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol. 1991; 9:62-9. [PubMed 1702147]

26. Neuroblastoma. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2004 Apr 21.

27. Philip T, Gentet JC, Carrie C et al. Phase II studies of combinations of drugs with high-dose carboplatin in neuroblastoma (800 mg/m2 to 1 g 250/m2): a report from the LMCE group. Prog Clin Biolog Res. 1988; 271:573-82.

28. Frappaz D, Michon J, Hartmann O et al. Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol. 1992; 10:1592-601. [PubMed 1403039]

29. Anon. Drugs of choice for cancer. Treat Guidel Med Lett. 2003; 1:41-52. [PubMed 15529105]

30. Broun ER, Nichols CR, Kneebone P et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Int Med. 1992; 117:124-8. [PubMed 1318648]

31. O’Brien MER, Tonge K, Blake P et al. Blindness associated with high-dose carboplatin. Lancet. 1992; 339:558. [PubMed 1346911]

32. McDonal BR, Kirmani S, Vasquez M et al. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med. 1991; 90:386-91. [PubMed 2003521]

33. Windom HH, McGuire WP III, Hamilton RG et al. Anaphylaxis to carboplatin - a new platinum chemotherapeutic agent. J All Clin Immunol. 1992; 90:681-3.

34. Welborn J, Meyers FJ, O’Grady LF. Renal salt wasting and carboplatinum. Ann Intern Med. 1988; 108:640.

35. Walker RW, Rosenblum MK, Kempin SJ et al. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer. 1989; 64:1017-20. [PubMed 2667747]

36. Kahn A, Hill JM Grater W et al. Atopic hypersensitivity to cis-diamminedichloroplatinum(II) and other platinum complexes. Cancer Res. 1975; 35:2766-70. [PubMed 50881]

37. Ozols RF. Optimal dosing with carboplatin. Semin Oncol. 1989; 16:14-8. [PubMed 2655094]

38. Egorin MJ. Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer. 1984; 44:5432-8.

39. Farhangi M, Weinstein SH. Carboplatin, etoposide, and bleomycin for treatment of stage IIC seminoma complicated by acute renal failure. Cancer Treat Rep. 1987; 71:1123-4. [PubMed 2445484]

40. Bishop JF. Current experience with high-dose carboplatin therapy. Semin Oncol. 1992; 19:150-4. [PubMed 1411626]

41. Staar S, Voilng P, Achterrath W et al. Carboplatin and simultaneous accelerated radiation in advanced squamous cell carcinoma of the head and neck. A phase II study. Proc Ann Meet Am Soc Clin Oncol. 1992; 11:A796.

42. Trissel LA. Handbook on injectable drugs. 8th ed. Bethesda, MD: American Society of Hospital Pharmacists, Inc; 1994:149-51.

43. van der Vijgh WJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet. 1991; 21:242-61. [PubMed 1760899]

44. Elferink F, van der Vijgh WJF, Klein I et al. Pharmacokinetics of carboplatin after IV administration. Cancer Treat Rep. 1987; 71:1231-7. [PubMed 3319135]

45. Smyth RD, Oguri S, Sakakibara T et al. Clinical pharmacokinetics of carboplatin. J Clin Pharmacol. 1987; 27:716.

46. Harland SJ, Newell DR, Siddik ZH et al. Pharmacokinetics of cis-diamminine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984; 44:1693-7. [PubMed 6367971]

47. Elferink F, van der Vijgh WJF, Klein I et al. Pharmacokinetics of IV and IP administered carboplatin. Phar Weekbl. 1986; 8. Abstract. (IDIS 224306)

48. Lee EJ, Egorin MJ, Van Echo DA et al. Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia. J Natl Cancer Inst. 1988; 80:131-5. [PubMed 3278122]

49. Oguri S, Sakakibara T, Mase H et al. Clinical pharmacokinetics of carboplatin. J Clin Pharmacol. 1988; 28:208-15. [PubMed 3283185]

50. Los G, Mutsaers PHA, Dubbelman R et al. Platinum distribution in rat and human peritoneal autopsy tumor samples after treatment with cDDP and CBDCA. Proc NCI-EORTC Symp 6; 1989. Abstract No. 220.

51. Los G, Nagel JC, McVie JG. Anti-tumor effect of cisplatin, carboplatin, mitoxantrone and doxorubicin on peritoneal tumor growth after intraperitoneal and intravenous chemotherapy: a comparative study. Sel Cancer Ther. 1990; 6:73-82. [PubMed 2195616]

52. Los G, Verdegaal EME, Mutsaers PHA et al. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy: a comparative study. Cancer Chemother Pharmacol. 1991;28:159-65.

53. Curt GA, Grygiel JJ, Corden BJ et al. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). Cancer Res. 1983; 43:4470-3. [PubMed 6347373]

54. Motzer RJ, Niedzwieck D, Isaacs M et al. Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol. 1990; 27:234-8. [PubMed 2176133]

55. Lee TC, Hook CC, Long HJ. Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy. Mayo Clin Proc. 69:80-2.

56. Allen JC, Walker R, Luks E et al. Carboplatin and recurrent childhood brain tumors. J Clin Oncol. 1987;5:459-63.

57. Friedman HS, Krischer JP, Burger P et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1992; 10:249-56. [PubMed 1732426]

58. Packer RJ, Ater J, Allen J et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997; 86:747-54. [PubMed 9126887]

59. Motzer RJ, Bosl GJ. High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J Natl Cancer Inst. 1992; 84:1703-9. [PubMed 1331482]

60. NIH Consensus Development Panel on Ovarian Cancer. NIH consensus conference on ovarian cancer: screening, treatment, and follow-up. JAMA. 1995; 273:491-7. [PubMed 7837369]

61. Weidmann B, Mulleneisen N, Bojko P et al. Hypersensitivity reactions to carboplatin. Cancer. 1994; 73:2218-22. [PubMed 8156529]

62. Chang SM, Fryberger S, Crouse V et al. Carboplatin hypersensitivity in children. Cancer. 1995; 75:1171-5. [PubMed 7850717]

63. Cheung Y, Cradock JC, Vishnuvajjala R et al. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm. 1987; 44:124-30. [PubMed 3548341]

64. Perrone RK, Kaplan MA, Bogardus JB. Extent of cisplatin formation in carboplatin admixtures. Am J Hosp Pharm. 1989; 46:258-9. [PubMed 2653024]

65. Wilms’ tumor. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2004 Apr 22.

66. Pein F, Tournade M, Zucker J et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms’ tumor—a phase II study by the French Society of Pediatric Oncology. J Clin Oncol. 1994; 12:931-6. [PubMed 8164044]

67. Langer CJ, Leighton J, McAleer C et al. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer. Semin Oncol. 1995; 22(Suppl 6):64-9. [PubMed 7541156]

68. Thigpen T, Vance R, Puneky L et al. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol. 1994; 55:S97-107. [PubMed 7835816]

69. Bertelsen K. Optimal chemotherapy of ovarian cancer with an old regimen. Ann Med. 1995; 27:121-5. [PubMed 7741990]

70. Hakes TB, Chalas E, Hoskins WJ et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol. 1992; 45:284-9. [PubMed 1612505]

71. Bertelsen K, Jakobsen A, Stroyer L et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group Trial (DACOVA). Gynecol Oncol. 1993; 49:30-6. [PubMed 8482557]

72. Ozols RF. USA update on paclitaxel in ovarian cancer. Ann Med. 1995; 27:127-30. [PubMed 7741991]

73. Ozols RF. Carboplatin and paclitaxel in ovarian cancer. Semin Oncol. 1995; 22:78-83. [PubMed 7541158]

74. Alberts DS, Garcia DJ. Total platinum dose versus platinum dose intensification in ovarian cancer treatment. Semin Oncol. 1994; 21(Suppl 2):11-5. [PubMed 8202716]

75. Ettinger DS. The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group Experience and a selected literature update. Semin Oncol. 1995; 22(Suppl 2):23-7. [PubMed 7846538]

76. Skarlos DV, Samantas E, Kosmidis P et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol. 1992; 5:601-7.

77. Bunn PA, Kelly K. New treatment agents for advanced small cell and non-small cell lung cancer. Semin Oncol. 1995; 22:53-63. [PubMed 7597434]

78. Bokemeyer C, Kohrmann O, Tischler J et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors. Ann Oncol. 1996; 7:1015-21. [PubMed 9037359]

79. Marina NM, Wilimas JA, Meyer WH et al. Refining therapeutic strategies for patients with resistant Wilms’ tumor. Am J Pediatr Hematol/Oncol. 1994; 16:296-300.

80. de Camargo B, Melaragno R, Saba e Silva N et al. Phase II study of carboplatin as a single drug for relapsed Wilms’ tumor: experience of the Brazilian Wilms’ Tumor Study Group. Med Pediatr Oncol. 1994; 22:258-60. [PubMed 8107657]

81. Bristol Laboratories. Paraplatin (carboplatin for injection) formula dosing. Princeton, NJ; 1995 Oct.

82. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7:1748-56. [PubMed 2681557]

83. Calvert AH. Dose optimisation of carboplatin in adults. Anticancer Res. 1994; 14:2273-8. [PubMed 7825958]

84. Chatelut E, Canal P, Brunner V et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995; 87:573-80. [PubMed 7752255]

85. Egorin MJ. Further refinement of carboplatin dosing. J Natl Cancer Inst. 1995; 87:555-6. [PubMed 7752248]

86. Chatelut E, Rostaing L, Gualano V et al. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron. 1994; 66:157-61. [PubMed 8139735]

87. Macdonald MR, Harrison RV, Wake M et al. Ototoxicity of carboplatin: comparing animal and clinical models at the hospital for sick children. J Otolaryngol. 1994; 23:151-9. [PubMed 8064951]

88. Tscherning C, Rubie H, Chancholle A et al. Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer. 1994; 73:1761-3. [PubMed 8156505]

89. Maloisel F, Kurtz JE, Andres E et al. Platin salts-induced hemolytic anemia: cisplatin- and the first case of carboplatin-induced hemolysis. Anticancer Drugs. 1995; 6:324-6. [PubMed 7795280]

90. Shlebak AA, Clark PI, Green JA. Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol. 1995; 35:349-51. [PubMed 7828281]

91. Sood AK, Gelder MS, Huang S-W et al. Anaphylaxis to carboplatin following multiple previous uncomplicated courses. Gynecol Oncol. 1995; 57:131-2. [PubMed 7705695]

92. Weiss RB, Christian MC. New cisplatin analogues in development: a review. Drugs. 1993; 46:360-77. [PubMed 7693428]

93. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Safety. 1995; 13:228-44. [PubMed 8573296]

94. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst. 1991; 83:613-20. [PubMed 1850806]

95. Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol. 1993; 33:691-7. [PubMed 7691898]

96. Ackland SP, Hillcoat BL. Immediate hypersensitivity to mannitol: a potential cause of apparent hypsersensitivity to cisplatin. Cancer Treat Rep. 1985; 69:562-3. [PubMed 3924402]

97. Bladder cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2005 Apr 19.

98. Pronzato P, Landucci M, Vaira F et al. Carboplatin, methotrexate, and vinblastine in outpatients with advanced transitional cell carcinoma of the bladder. Am J Clin Oncol. 1995; 18:223-5. [PubMed 7747710]

99. Boccardo F, Pace M, Guarneri D et al. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. Cancer. 1994; 73:1932-6. [PubMed 8137220]

100. Thrasher JB, Crawford ED. Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol. 1993; 149:957-72. [PubMed 8483247]

101. Bellmunt J, Albanell J, Gallego OS et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer. 1992; 70:1974-9. [PubMed 1525774]

102. Retinoblastoma. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2004 Apr 21.

103. Du Bois A, Vach W, Thomssen C et al. Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents. Acta Oncol. 1994; 33:531-5. [PubMed 7917367]

104. Saunders MP, Denton CP, O’Brien ME et al. Hypersensitivity reactions to cisplatin and carboplatin—a report on six cases. Ann Oncol. 1992; 3:574-6. [PubMed 1498081]

105. Hendrick AM, Simmons D, Cantwell BM. Allergic reactions to carboplatin. Ann Oncol. 1992; 3:239-40. [PubMed 1586624]

106. Doz F, Neuenschwander S, Plantaz D et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Societe Francaise d’Oncologie Pediatrique. J Clin Oncol. 1995; 13:902-9. [PubMed 7707117]

107. Egorin MJ, Van Echo DA, Olman EA et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res. 1985; 45:6502-6. [PubMed 3904984]

108. Fish RG, Shelley MD, Griffiths H et al. Correspondence re: M.J. Egorin et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1987; 47:3606-7. [PubMed 3581092]

109. Gore ME, Calvert AH, Smith LE. High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. Eur J Cancer Clin Oncol. 1987; 23:1391-7. [PubMed 2824209]

110. Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol. 1989; 7:651-61. [PubMed 2651580]

111. Kennedy IC, Fitzharris BM, Colls BM et al. Carboplatin is ototoxic. Cancer Chemother Pharmacol. 1990; 26:232-4. [PubMed 2192812]

112. Siddik ZH, Newell DR, Boxall FE et al. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol. 1987; 36:1925-32. [PubMed 3297068]

113. Food and Drug Administration. Labeling and prescription drug advertising; content and format for labeling for human prescription drugs. 21 CFR Parts 201 and 202. Final Rule. [Docket No. 75N-0066] Fed Regist. 1979; 44:37434-67.

114. Chu G, Mantin R, Shen Y-M et al. Massive cisplatin overdose by accidental substitution for carboplatin. Cancer. 1993; 72:3707-14. [PubMed 8252487]

115. Cohen MR. Safety alert-overdoses of platinol (cisplatin) and paraplatin (carboplatin) and a dangerous abbreviation. Hosp Pharm. 1992; 27:991-2.

116. Anon. Medication errors cause death. Drug Prod Qual Rev. 1992 Jul; No. 31.

117. Pike IM, Arbus MH. Cisplatin overdosage. Am J Hosp Pharm. 1992; 49:1668. [PubMed 1621717]

118. Department of Health and Human Services, Food and Drug Administration. Subpart BLabeling requirements for prescription drugs and/or insulin. (21 CFR Ch. 1 (4-1-87 Ed.)). 1987:18-24.

119. Bin P, Boddy AV, English MW et al. The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review. Anticancer Res. 1994; 14:2279-83. [PubMed 7825959]

120. Newell DR, Pearson ADJ, Balmanno K et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosage formula. J Clin Oncol. 1993; 11:2314-23. [PubMed 8246021]

121. Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995; 13:1860-70. [PubMed 7543559]

122. Eastman A. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum (II) and cis-dichloro (ethylenediamine) platinum (II). Biochemistry. 1983; 22:3927-33. [PubMed 6225458]

123. Meijer C, Mulder NH, Hospers GA et al. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br J Cancer. 1990; 62:72-7. [PubMed 2390486]

124. Fram RJ, Woda BA, Wilson JM et al. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells. Cancer Res. 1990; 50:72-7. [PubMed 2293559]

125. Godwin AK, Meister A, O’Dwyer PJ et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 1992; 89:3070-4. [PubMed 1348364]

126. Eastman A, Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry. 1988; 27:4730-4. [PubMed 3167012]

127. Lai GM, Ozols RF, Smyth JF et al. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol. 1988; 37:4597-600. [PubMed 3144285]

128. Metastatic squamous neck cancer with occult primary. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Jun.

129. Adult brain tumor. From CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Jul.

130. Childhood medulloblastoma. From CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Jun.

131. Vaughn DJ, Malkowicz SB, Zoltick B et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol. 1998; 16:255-60. [PubMed 9440750]

132. Non-small cell lung cancer. From CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 May 17.

133. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311:899-909. [PubMed 7580546]

134. Finley RS. Paraplatin (carboplatin for injection) formulary information. Evansville, IN: Bristol Laboratories; 1989 Feb.

135. Cancer of the head and neck. In: DeVita VT, Hellman SA, Rosenberg S, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia: J. B. Lippincott Co; 1993:574-630.

136. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med. 1993; 329:1790-6. [PubMed 8232489]

137. Reviewers’ comments (personal observations).

138. Bristol-Myers Squibb, Princeton, NJ: Personal communication.

139. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334:1-6. [PubMed 7494563]

140. Chazard M, Boutan-Laruze A. High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. Eur J Cancer. 1993; 29A:1504-9. [PubMed 8217352]

141. Klastersky J, Sculier JP, Lacroix H et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer. European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol. 1990; 8:1556-62. [PubMed 2167953]

142. Pignon JP, Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992; 327:1618-24. [PubMed 1331787]

143. Scher HI, Shipley WU, Herr HW. Cancer of the bladder. In: DeVita VT Jr, Hellman S, Rosenberg SA eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997:1300-22.

144. Reviewers’ comments (personal observations) on bladder cancer.

145. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000; 18:3084-92. [PubMed 10963636]

146. Petrioli R, Frediani B, Manganelli A et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: a randomized phase II study. Cancer. 1996; 77:344-51. [PubMed 8625244]

147. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000; 92:699-708. [PubMed 10793106]

148. Bonomi P, Kim K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000; 18:623-31. [PubMed 10653877]

149. Ramanathan RK, Belani CP. Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin Oncol. 1997; 24:440-54. [PubMed 9280224]

150. Johnson DH, Paul DM, Hande KR et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol. 1996; 2054-60. (IDIS 370183)

151. Belani CP, Natale RB, Lee JS et al. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 1998; 17:A1751.

152. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002; 13:1539-49. [PubMed 12377641]

153. Skarlos DV, Samantas E, Kosmidis P et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol. 1994; 5:601-7. [PubMed 7993835]

154. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999; 340:1137-43. [PubMed 10202164]

155. Keys HM, Bundy BN, Stehman FB et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999; 340:1154-61. [PubMed 10202166]

156. Peters WA 3rd, Liu PY, Barrett RJ 2nd et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000; 18:1606-13. [PubMed 10764420]

157. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340:1144-53. [PubMed 10202165]

158. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999; 17:1339-48. [PubMed 10334517]

159. Cervical cancer. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Jun.

160. Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med. 1996; 334:1030-8. [PubMed 8598842]

161. Cervical cancer. NIH Consens Statement. 1996 April 1–3; 14:1-38.

162. Omura GA. Chemotherapy for stage IVB or recurrent cancer of the uterine cervix. J Natl Cancer Inst Monogr. 1996; (21):123-6. [PubMed 9023841]

163. McGuire WP 3d, Arseneau J, Blessing JA et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989; 7:1462-8. [PubMed 2674333]

164. Weiss GR, Green S, Hannigan EV et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol. 1990; 39:332-6. [PubMed 2258080]

165. Lira-Puerto V, Silva A, Morris M et al. Phase II trial of carboplatin or iproplatin in cervical cancer. Cancer Chemother Pharmacol. 1991; 28:391-6. [PubMed 1914084]

166. Reviewers’ comments (personal observations) on cervical cancer.

167. Aabo K, Adams M, Adnitt P et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists’ Group. Br J Cancer. 1998; 78:1479-87. [PubMed 9836481]

168. Redman BG, Smith DC, Flaherty L et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol. 1998; 16:1844-8. [PubMed 9586899]

169. Childhood brain tumor. From CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Jun.

170. Warnick RE, Prados MD, Mack EE et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol. 1994; 19:69-74. [PubMed 7815106]

171. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol. 1991; 9:860-4. [PubMed 1849986]

172. Guruangan S, Dunkel IJ, Goldman S et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol. 1998; 16:2486-93. [PubMed 9667268]

173. Dunkel IJ, Boyett JM, Yates A et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children’s Cancer Group. J Clin Oncol. 1998; 16:222-8. [PubMed 9440746]

174. Heideman RL, Kovnar EH, Kellie SJ et al. Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol. 1995; 13:2247-54. [PubMed 7666082]

175. Mason WP, Grovas A, Halpern S et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol. 1998; 16:210-21. [PubMed 9440745]

176. Matsutani M, Sano K, Takakura K et al. Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg. 1997; 86:446-55. [PubMed 9046301]

177. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346:92-8. [PubMed 11784875]

178. Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19:3210-8. [PubMed 11432888]

179. Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003; 95:113-25. [PubMed 12529344]

180. Colombo N, Guthrie D, Chiari S et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003; 95:125-32. [PubMed 12529345]

181. Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003; 95:105-12. [PubMed 12529343]

182. Young RC. Early-stage ovarian cancer: to treat or not to treat. J Natl Cancer Inst. 2003; 95:94-5. [PubMed 12529336]

183. Piccart MJ, Bertelsen K, Stuart G et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer. 2003;13 Suppl 2:144-8.

184. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21:3194-200. [PubMed 12860964]

185. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95:1320-30. [PubMed 12953086]

186. Gore M. Carboplatin equals cisplatin: but how do I prescribe it? J Clin Oncol. 2003; 21:3183-5. Editorial.

187. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002; 360:505-15. [PubMed 12241653]

188. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 361:2099-106. [PubMed 12826431]

189. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Proc ASCO. 2004; Abstract No. 5005.

190. Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004; 100:1639-45. [PubMed 15073851]

191. Ozols RF, Markman M, Thigpen JT. ICON3 and chemotherapy for ovarian cancer. Lancet. 2002; 360:2086-7. [PubMed 12504453]

192. McGuire W, Piccart MJ. The European Canadian Intergroup trial (OV10 trial) and the US Gynaecologic Oncology Group trial (GOG 111). Int J Gynecol Cancer. 2004; 14:698.

193. Horwich A, Sleijfer DT, Fossa SD et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. 1997; 15:1844-52. [PubMed 9164194]

194. Bhatia S, Abonour R, Porcu P et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol. 2000; 18:3346-51. [PubMed 11013274]

195. Miller D, protocol chair. Phase III randomized study of doxorubicin, cisplatin, paclitaxel, and filgrastim (G-CSF) versus carboplatin and paclitaxel in patients with stage III or IV or recurrent endometrial cancer. Protocol ID: GOG-0209. Last modified: 5/19/2006. National Cancer Institute: Clinical Trials (database).

196. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96:1682-91. [PubMed 15547181]

197. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group. J Clin Oncol. 2003; 21:3016-24. [PubMed 12837811]

198. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20:4285-91. [PubMed 12409326]

199. Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006; 24:2786-92. [PubMed 16782917]

200. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992; 10:1245-51. [PubMed 1634913]

201. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24:2932-47. [PubMed 16717289]

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:189-92.

b. Bedford. Carboplatin for injection prescribing information. Bedfore, OH; 2004 Mar.